Akebia Therapeutics Inc. buy BTIG Research
Start price
29.11.23
/
50%
€0.92
Target price
29.11.24
€3.64
Performance (%)
40.67%
Price
07.05.24
€1.30
Summary
This prediction is currently active. With a performance of 40.67% the BUY prediction by BTIG_Research is a big success. This prediction currently runs until 29.11.24. The prediction end date can be changed by BTIG_Research at any time. BTIG_Research has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Akebia Therapeutics Inc. | 10.289% | 10.289% |
iShares Core DAX® | 2.831% | 1.236% |
iShares Nasdaq 100 | 2.918% | 0.640% |
iShares Nikkei 225® | 2.007% | -2.135% |
iShares S&P 500 | 2.257% | 0.451% |
Comments by BTIG_Research for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat